
doi: 10.1007/bf02967573
pmid: 12016388
Health-related quality of life (HRQOL) has become one of the important endpoints in cancer treatments. However, a relatively small proportion of oncologists truly understand the concepts and uses of QOL assessments. In this article, I discuss psychometric properties that should be verified with QOL instruments, scope of the QOL concepts that should be assessed in oncology, how to choose the appropriate measures, and cross-cultural validation and statistical issues. Several examples of QOL assessments in recent clinical trials in oncology are also reviewed.
Clinical Trials as Topic, Breast Neoplasms, Prognosis, Combined Modality Therapy, Disease-Free Survival, Survival Rate, Treatment Outcome, Chemotherapy, Adjuvant, Quality of Life, Health Status Indicators, Humans, Female, Radiotherapy, Adjuvant, Mastectomy, Neoplasm Staging
Clinical Trials as Topic, Breast Neoplasms, Prognosis, Combined Modality Therapy, Disease-Free Survival, Survival Rate, Treatment Outcome, Chemotherapy, Adjuvant, Quality of Life, Health Status Indicators, Humans, Female, Radiotherapy, Adjuvant, Mastectomy, Neoplasm Staging
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 16 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
